New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
08:03 EDTSLPSimulations Plus announces 'success' in COX-2, COX-1 drug design project
Simulations Plus announced that its second new chemical entity initiative, which involved using Simulations Plus software to design molecules to inhibit COX-2, has been a success as determined by synthesis and testing by a third-party lab. Three of the four molecules it has designed are potent inhibitors of both cyclooxygenase-2 and COX-1 enzymes. The fourth inhibits COX-2 but only weakly inhibits COX-1. The company said, "This project was more challenging than the malaria NCE project we completed two years ago because this time our goal was to inhibit two targets with a single molecule while also providing good absorption, distribution, metabolism, excretion, and toxicity properties."
News For SLP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
16:13 EDTSLPSimulations Plus reports Q4 EPS 1.3c, consensus 2c
Reports Q4 revenue $2M, consensus $1.81M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use